HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco

Vaccine

Volumn 29, Issue 10, 2011, Pages 1991-1996

  Etcheverry, M Florencia ^a   Lum, Paula J ^b   Evans, Jennifer L ^b   Sanchez, Emilia ^c   de Lazzari, Elisa ^a   Mendez Arancibia, Eva ^a   Sierra, Ernesto ^d   Gatell, José M ^a   Page, Kimberly ^b   Joseph, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITAT RAMON LLULL   (Spain)

^d Red Cross Centre   (Spain)

Author keywords

HIV; HIV vaccines; IDUs; Injection and non injection drug users; Willingness to participate in future trials

Indexed keywords

HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DRUG ABUSE; FEMALE; HEPATITIS B; HEPATITIS C; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PATIENT PARTICIPATION; PRIORITY JOURNAL; SEROPREVALENCE; SEXUAL BEHAVIOR; SPAIN; UNITED STATES; VACCINATION;

ADULT; AIDS VACCINES; CLINICAL TRIALS AS TOPIC; DRUG USERS; FEMALE; HUMANS; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; SAN FRANCISCO; SPAIN; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 79951720951     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.043     Document Type: Article

References (34)

1. European Centre for Disease Prevention and Control: HIV infection in Europe: 25 years into the pandemic 2007, Stockholm, European Centre for Disease Prevention and Control, http://www.eu2007.de/en/News/download/docs/Maerz/0312-BSGV/040Background.pdf.
2. De la Fuente L., Bravo M.J., Toro C., Brugal M.T., Barrio G., Soriano V., et al. Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes. Journal of Epidemiology and Community Health 2006, 60:537-542.
3. Barrio G., De La Fuente L., Toro C., Brugal T.M., Soriano V., Gonzalez F., et al. Prevalence of HIV infection among young adult injecting and non-injecting heroin users in Spain in the era of harm reduction programmes: gender differences and other related factors. Epidemiology Infections 2007, 135(4):592-603.
4. Tyndall M., Currie S.L., Spittal P., Li K., Wood E., O'Shaughnessy M.V., et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. Journal of Acquired Immune Deficiency Syndromes 2003, 17:887-893.
5. United Nations Office on Drugs and Crime (UNODC): annual report 2007, United Nations, Vienna, http://www.unodc.org/pdf/annual_report_2007/AR06_fullreport.pdf.
6. Huntington S., Folch C., González V., Meroño M., Ncube F., Casabona J. Prevalence of human immunodeficiency virus and hepatitis C virus, and associated factors among injecting drug users in Catalonia. Enfermedades Infecciosas Microbiología Clínica 2010, 28(4):236-238.
7. EuroHIV HIV/AIDS surveillance in Europe. Mid-year report 2007 2007, Institut de Veille Sanitaire, Saint-Maurice.
8. Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT) Sistema integrat de vigilància epidemiològica de Sida/VIH/ITS a Catalunya (SIVES): informe bianual 2008, Generalitat de Catalunya, Departament de Salut, Barcelona.
9. Muga R., Sanvisens A., Bolao F., Tor J., Santesmases J., Pujol R., et al. Significant reductions of HIV prevalence but not of hepatitis C virus infections in injection drug users from metropolitan Barcelona: 1987-2001. Drug and Alcohol Dependence 2006, 2(Suppl. 1):S29-S33.
10. Scheinmann R., Hagan H., Lelutiu-Weinberger C., Stern R., Des Jarlais D.C., Flom P.L., et al. Non-injection drug use and hepatitis C virus: a systematic. Drug and Alcohol Dependence 2007, 89(1):1-12.
11. Santana Rodríguez O.E., Malé Gil M.L., Hernández Santana J.F., Limiñana Cañal J.M., Martín Sánchez A.M. Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain. European Journal of Epidemiology 1998, 14(6):555-561.
12. Des Jarlais D.C., Perlis T., Arasteh K., Torian L.V., Hagan H., Beatrice S., et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City 1990-2001. Journal of Acquired Immune Deficiency Syndromes 2005, 19(Suppl. 3):S20-S25.
13. Kral A.H., Page-Shafer K., Edlin B.R., Kellogg T., Riley E., Gee L., et al. Persistent HIV incidence among injection drug users in San Francisco during the 1990s: results of five studies. Journal of Acquired Immune Deficiency Syndromes 2004, 37(5):1667-1669.
14. Moss A.R., Vranizan K., Gorter R., Bacchetti P., Watters J., Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. Journal of Acquired Immune Deficiency Syndromes 1994, 8(2):223-231.
15. Hahn J.A., Page-Shafer K., Lum P.J., Ochoa K., Moss A.R. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001, 34:180-187.
16. Kral A.H., Lorvick J., Edlin B.R. Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. Journal of Acquired Immune Deficiency Syndromes 2000, 24(2):162-167.
17. Inglez-Dias A., Hahn J.A., Lum P.J., Evans J., Davidson P., Page-Shafer K. Trends in methamphetamine use in young injection drug users in San Francisco from 1998 to 2004: the UFO Study. Drug and Alcohol Review 2008, 27(3):286-291.
18. Joseph J., Etcheverry F., Alcami J., Gatell J.M. A safe, effective and affordable HIV vaccine-an urgent global need. Journal of Acquired Immune Deficiency Syndromes Reviews 2005, 7(3):131-138.
19. Letvin N.L., Barouch D.H., Montefiori D.C. Prospects for vaccine protection against HIV-1 infection and AIDS. Annual Review of Immunology 2002, 20:73-99.
20. Sanz B., Torres A.M., Schumacher R. Características sociodemográficas y utilización de Servicios Sanitarios por la población inmigrante residente en un área de la Comunidad de Madrid. Atención Primaria 2000, 26(5):314-318.
21. Etcheverry M.F., de Lazzari E., Fuchs J.D., Meroño M., Sierra E., Del Romero J., et al. Pilot study assessing HIV vaccine trial readiness among female sex workers, injection and non-injection drug users, and men who have sex with men in Spain. AIDS and Behaviour 2010, 14(3):607-617.
22. Koblin B.A., Holte S., Lenderking B., Heagerty P. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. The HIVNET Vaccine Preparedness Study Protocol Team. Journal of Acquired Immune Deficiency Syndrome 2000, 24(5):451-457.
23. Page Shafer K.P., Hahn J.A., Lum P.J., Ochoa K., Graves A., Moss A. Prevalence and correlates of HIV infection among young injection drug users in San Francisco. Journal of Acquired Immune Deficiency Syndromes 2002, 31(4).
24. Kral A.H., Lorvick J., Gee L., Bacchetti P., Rawal B., Busch M., et al. Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. American Journal of Epidemiology 2003, 157(10):915-922.
25. Colfax G., Buchbinder S., Vamshidar G., Celum C., McKirnan D., Neidig J., et al. Motivations for participating in an HIV vaccine efficacy trial. Journal of Acquired Immune Deficiency Syndromes 2005, 39(3):359-364.
26. Bolumar F., Hernandez-Aguado I., Ferrer L., Ruiz I., Aviño M.J., Rebagliato M. Prevalence of antibiotics to hepatitis C in a population of intravenous drug users in Valencia, Spain, 1990-1992. American Journal of Epidemiology 1996, 143(6):578-587.
27. Judd A., Hutchinson S., Wadd S., Hickman M., Taylor A., Jones S., et al. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. Journal of Viral Hepatitis 2005, 12(6):655-662.
28. Muga R., Sanvisens A., Bolao F., Tor J., Santesmases J., Pujol R., et al. Significant reductions of HIV prevalence but not of hepatitis C virus infections in injection drug users from metropolitan Barcelona: 1987-2001. Drug and Alcohol Dependence 2006, (Suppl 1):29-33.
29. Roy E., Alary M., Morissette C., Leclerc P., Boudreau J.F., Parent R., et al. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. International Journal of STD and AIDS 2007, 18(1):23-27.
30. Roy K.M., Hutchinson S.J., Wadd S., Taylor A., Cameron S.O., Burns S., et al. Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them. Epidemiology and Infection 2007, 135(3):433-442.
31. Verachai V., Phutiprawan T., Theamboonlers A., Chinchai T., Tanprasert S., Haagmans B.L., et al. Prevalence and genotypes of hepatitis C virus infection among drug addicts and blood donors in Thailand. The Southeast Asian. Journal of Tropical Medicine and Public Health 2002, 33(4):849-851.
32. Mesquita P.E., Granato C.F., Castelo A. Risk factors associated with hepatitis C virus HCV infection among prostitutes and their clients in the city of Santos, São Paulo State, Brazil. Journal of Medical Virology 1997, 51(4):338-343.
33. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. The Lancet Infectious Disease 2005, 5(9):558-567.
34. Terrault N.A. Sex and hepatitis C. American Journal of Gastroenterology 2005, 100(4):825-826.